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ABSTRACT Tuberculosis (TB) caused by Mycobacte-
rium tuberculosis constitutes an ongoing threat to global
health. An antigen that can induce dendritic cell (DC)
maturation and lead to enhanced cellular immunity is
crucial to the development of an effective TB vaccine.
Here, we investigated the functional roles and the
related signaling mechanism of the Rv0577 protein, a
M. tuberculosis complex-restricted secreted protein in-
volved in the methylglyoxal detoxification pathway.
Rv0577 recognizes Toll-like receptor 2 (TLR2) and
functionally induces DC maturation by augmenting the
expression of cell surface molecules (CD80, CD86, and
MHC class I and II) and proinflammatory cytokine
production (TNF-, IL-1, IL-6, and IL-12p70) in DCs
on MyD88-dependent signaling, mitogen-activated pro-
tein kinases, and nuclear factor B signaling pathways.
In addition, Rv0577-treated DCs activated naive T cells,
effectively polarized CD4 and CD8 T cells to secrete
IFN- and IL-2, and induced T-cell proliferation, indi-
cating that this protein possibly contributes to Th1-
polarization of the immune response. More important,
unlike LPS, Rv0577-treated DCs specifically induced
the proliferation of memory CD4/CD8CD44high
CD62Llow T cells in the spleen of M. tuberculosis-
infected mice in a TLR2-dependent manner. Taken
together, these findings suggest that Rv0577 may regu-
late innate and adaptive immunity by interacting with
TLR2, a finding that could be helpful in the design of
new TB vaccines.—Byun, E.-H., Kim, W. S., Kim, J.-S.,
Jung, I. D., Park, Y.-M., Kim, H.-J., Cho, S.-N., Shin, S. J.
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MYCOBACTERIUM TUBERCULOSIS causes tuberculosis (TB)
and is one of the most successful intracellular patho-
gens in humans, with approximately one-third of the
world’s population infected (1). The host immune
response has been found to play a critical role in both
control of and protective immunity against the patho-
gen by targeting antigens (Ags) secreted by M. tubercu-
losis (2). Consequently, identification and characteriza-
tion of M. tuberculosis Ags is essential to understanding
host–pathogen interactions and facilitating the devel-
opment of prospective vaccine candidates (2, 3).
Dendritic cells (DCs) are potent antigen-presenting
cells (APCs) that play a pivotal role in controlling
immune responses to M. tuberculosis (4). Many studies
regarding the function of DCs on M. tuberculosis infec-
tion have mainly focused on the ability of these cells by
interacting with M. tuberculosis or its Ags to express
major histocompatability complex (MHC) class II and
costimulatory molecules, including CD80 and CD86,
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Abbreviations: Ag, antigen; APC, antigen-presenting cell;
BMDC, bone marrow-derived dendritic cell; BSA, bovine serum
albumin; CFSE, carboxyfluorescein diacetate succinimidyl ester;
DC, dendritic cell; DMSO, dimethyl sulfoxide; ELISA, enzyme-
linked immunosorbent assay; FITC, fluorescein isothiocyanate;
GM-CSF, granulocyte-macrophage colony-stimulating factor;
IFN-, interferon-; IgG, immunoglobulin G; IB-, inhibitory
B-; IL, interleukin; LAL, Limulus amoebocyte lysate; LPS,
lipopolysaccharide; MAPK, mitogen activated protein kinase;
MHC, major histocompatability complex; MLR, mixed lympho-
cyte reaction; MyD88, myeloid differentiation factor 88; NF-B,
nuclear factor-B; PBS, phosphate-buffered saline; PE, phyco-
erythrin; PmB, polymyxin B; PRR, pattern recognition receptor;
SDS-PAGE, sulfate-polyacrylamide gel electrophoresis; TB, tu-
berculosis; TCR, T-cell receptor; TIR, Toll/interleukin-1 recep-
tor homology; TLR, Toll-like receptor; TNF-, tumor necrosis
factor-; TRIF, TIR domain containing adapter inducing inter-
feron-; WT, wild type
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which induce T cell proliferation (5, 6). Immature DCs
(iDCs) have the ability to capture and internalize Ags
via pattern recognition receptors (PRRs), recognizing
conserved molecular moieties that distinguish a broad
specificity of microbial products, the so-called patho-
gen-associated molecular patterns (PAMPs) (6). On
PAMP ligation by PRRs, activation of appropriate im-
mune responses to TB can be initiated to maintain
well-regulated immunological homeostasis (7). Among
various PRRs, Toll-like receptors (TLRs) play a crucial
role in the activation of the cellular immune response
against M. tuberculosis infection (8). Recognition of
microbial components by TLRs plays a central role in
whether the immune system will respond to a particular
microbial infection (8). The intracellular signal trans-
duction activated via TLRs is initially mediated through
the Toll/interleukin-1 receptor homology (TIR) do-
mains. Activation of signaling through TIR domains
results in recruitment of the adaptor molecule myeloid
differentiation factor 88 (MyD88) and/or TIR domain
containing adapter inducing interferon- (TRIF), ulti-
mately leads to activation of mitogen-activated protein
kinases (MAPKs) and nuclear factor B (NF-B) (8).
This signaling process enables DCs to become potent
APCs to initiate robust innate immunity by up-regulat-
ing the expression of surface molecules including
CD80, CD86, and MHC class I and II and a number of
cytokines such as interleukin (IL)-1, IL-6, IL-12, and
tumor necrosis factor- (TNF-), and losing endocytic/
phagocytic receptors (6). Moreover, these mature DCs
migrate to draining lymph nodes where they present
these Ags and stimulate naive T lymphocytes to initiate
an immune response (6). As described above, the
maturation of DCs may be particularly important for
the elicitation of both primary and secondary immune
responses to pathogens. Recently, several studies have
reported that M. tuberculosis Ags induced the matura-
tion and activation of DCs in a TLR2-dependent man-
ner. For example, M. tuberculosis Ags, such as Rv1196,
Rv0978c, and Rv0754, recognize TLR2 and induce
maturation and activation of DCs (9–11). In addition,
DCs matured by M. tuberculosis Ags relocate to the
lymph nodes, where they produce proinflammatory
cytokines and the development of an adaptive immune
response that includes helper (CD4) T cells, cytotoxic
(CD8) T cells,  T cells, and the production of
interferon- (IFN-) and TNF- (key cytokines in im-
munity to TB; refs. 12, 13).
M. tuberculosis Rv0577 (also known as CFP32 and
TB27.3) is a complex-restricted secreted protein absent
from environmental mycobacteria but expressed dur-
ing the course of infection (14). Notably, M. tuberculosis
clinical isolates appear to express more Rv0577 than
laboratory-adapted M. tuberculosis strains and other M.
tuberculosis complex subspecies (including the Mycobac-
terium bovis BCG strain; ref. 14). Recently, CFP32 was
recognized as the enzymatic mediator of M. tuberculosis-
specific neutral red dye cytochemical staining, a classic
test used to differentiate virulent M. tuberculosis from
nontuberculous mycobacteria (15). Moreover, native
Rv0577 has been detected in the sputum of M. tubercu-
losis-infected individuals and may be useful as a possible
diagnostic potential (14). Furthermore, a recent study
has suggested that Rv0577 is associated with the meth-
ylglyoxal detoxification pathway as a potential glyoxy-
lase (16), which suggests that it is a candidate target of
pyrimidine-imidazoles. Although comparative analyses
suggest that the rv0577 gene product may be important
to the pathogenesis of M. tuberculosis and a biological
function for Rv0577 has been identified, the immuno-
logical function of this protein has not been elucidated,
especially its role in innate and adaptive immunity. In
the present study, we investigated the molecular basis of




Specific pathogen-free female C57BL/6 (H-2Kb and I-Ab),
BALB/c (H-2Kd and I-Ad), C57BL/6J TLR2-knockout mice
(TLR2/; B6.129-Tlr2tm1Kir/J), C57BL/10 TLR4 knockout
mice (TLR4/; C57BL/10ScNJ), C57BL/6 OT-1 and OT-2
T-cell receptor (TCR) transgenic mice, at 5-6 wk of age were
purchased from the Jackson Laboratory (Bar Harbor, ME,
USA) and maintained under barrier conditions in a biohaz-
ard animal room at the Medical Research Center, Chungnam
National University. The animals were fed a sterile commer-
cial mouse diet and provided with water ad libitum. The
animal experiments complied with the ethical and experi-
ment regulations for animal care at Chungnam National
University.
Animal infection study was performed in a BL-3 biohazard
animal facility at Yonsei University Medical Research Center.
Briefly, 6-wk-old BALB/c mice were exposed to a predeter-
mined dose of M. tuberculosis H37Rv (ATCC27294) for 60 min
in the inhalation chamber of an airborne infection apparatus
(Glas-Col, Terre Haute, IN, USA) (17). Bacteria were counted
1 d after exposure, and200 viable M. tuberculosis were found
to have been delivered to the lungs. At 8 wk postinfection,
5–6 mice were euthanized, and their spleens were collected
to conduct the subsequent experiments, including mixed
lymphocyte reactions (MLRs). All infection-related experi-
ments were done according to the regulation of the Yonsei
University Health System Institutional Animal Care and Use
Committee.
Abs and reagents
Recombinant mouse granulocyte-macrophage colony stimu-
lating factor (GM-CSF) and interleukin-4 (IL-4), and the
fluorescein isothiocyanate (FITC)-annexin V/propidium io-
dide kit were purchased from R&D Systems (Minneapolis,
MN, USA). Dextran-FITC (molecular mass, 40,000 Da) was
obtained from Sigma (St. Louis, MO, USA). Lipopolysaccha-
ride (LPS) from Escherichia coli O111:B4 and palmitoyl-3-Cys-
Ser-(Lys)4 (Pam3) were purchased from Sigma and Invitro-
gen (San Diego, CA, USA), respectively. An endotoxin filter
(END-X) and an endotoxin removal resin (END-X B15) were
acquired from Associates of Cape Cod (East Falmouth, MA,
USA). Peptron (Daejeon, South Korea)synthesized the OT-I
peptide (OVA257–264) and OT-II peptide (OVA323–339). Anti-
phosphorylated ERK1/2 monoclonal Ab, anti-ERK1/2 poly-
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clonal Ab, anti-phosphorylated JNK monoclonal Ab, anti-JNK
polyclonal Ab, anti-phosphorylated p38 monoclonal Ab, anti-
p38 polyclonal Ab, anti-NF-B (p65) polyclonal Ab, anti-
phosphorylated inhibitory B- (IB-) monoclonal Ab, anti-
IB- monoclonal Ab, and anti-lamin B polyclonal Ab were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). HRP-conjugated anti-mouse immunoglobulin G
(IgG) Ab and HRP-conjugated anti-rabbit Ab were obtained
from Calbiochem (San Diego, CA, USA), and anti--actin
mAb (AC-15) was purchased from Sigma. FITC-conjugated
mAb to CD11c, CD62L, and IFN-; APC-conjugated mAb to
IL-12p70; Alexa647-conjugated mAb to CCR3; PerCP-cy5.5-
conjugated mAb to CD4 and CD8; phycoerythrin (PE)-
conjugated mAb to IL-4, CD80, CD86, MHC class I, MHC
class II, CD44, and CXCR3; PE-cy5-conjugated mAb to CD4
and CD8; and PE-cy7-conjugated mAb to IL-2 were pur-
chased from eBioscience (San Diego, CA, USA). IL-6, IL-1,
TNF-, IL-2, IL-4, and IFN- enzyme-linked immunosorbent
assay (ELISA) kits were obtained from eBioscience, and
IL-12p70 and IL-10 ELISA kit were obtained from BD Biosci-
ences (San Diego, CA, USA).
Expression and purification of recombinant Rv0577
To produce recombinant Rv0577 protein, the corresponding
gene was amplified by PCR using M. tuberculosis H37Rv
ATCC27294 genomic DNA as template and the following
primers: forward, 5=-GGGCCCCATATGCCCAAGAGAAGC-
GAATACAGC-3=, and reverse, 5=-GGGCCCAAGCTTCTATT-
GCTGCGGTGCGGG-3=. The product of rv0577 was cut with
NdeI and HindIII. Both the products were inserted into
pET28a () vector (Novagen, Madison, WI, USA), and the
resultants were sequenced. The recombinant plasmids con-
taining rv0577 were transformed into E. coli BL21 cells by heat
shock for 1 min at 42°C. The overexpressed Rv0577 was
prepared with slight modifications, as described previously
(18). Briefly, E. coli containing recombinant plasmid were
grown at 37°C until the optical density (OD) at 600 nm was
0.4 to 0.5 and then induced with 1 mM isopropyl-d-thiogalac-
topyranoside (IPTG; ELPIS-Biotech, Daejeon, South Korea).
The bacterial cells were then harvested by centrifugation and
suspended in 20 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 20 mM
imidazole, and 1 mM phenylmethylsulfonyl fluoride (Sigma);
and lysed by sonication. The recombinant Rv0577 was puri-
fied by nickel-nitrilotriacetic acid (Ni-NTA) agarose chroma-
tography in accordance with the manufacturer’s instructions
(Qiagen, Chatsworth, CA, USA). Each purification step was
analyzed by 13.5% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) with Coomassie brilliant blue
stain and immunoblot using anti-His antibodies (Santa Cruz
Biotechnology). The purified protein was pooled, concen-
trated, and dialyzed against phosphate-buffered saline (PBS;
pH 7.4). To remove endotoxin contamination, the dialyzed
recombinant protein was incubated with polymyxin B (PmB)-
agarose (Sigma) for 6 h at 4°C. Lastly, purified endotoxin-free
recombinant protein was filter-sterilized and frozen at70°C.
The protein concentration was estimated with the bicin-
choninic acid protein assay kit (Pierce, Rockford, IL, USA)
with bovine serum albumin (BSA) as the standard. Residual
LPS in the Rv0577 preparation was determined using the
Limulus amoebocyte lysate (LAL) test (Lonza, Basel, Switzer-
land), according to the manufacturer’s instructions. The
purity of Rv0577 was evaluated by Coomassie blue staining,
silver nitrate staining, and Western blot using an anti-histi-
dine antibody. In addition, the purity of Rv0577 was quanti-
fied by Quantity One software (Bio-Rad, Hercules, CA, USA)
and calculated by dividing the intensity per square millimeter
of the Rv0577-specific band by that of all the protein bands in
the preparation lane.
Generation of polyclonal antibody to Rv0577
The polyclonal antibodies against Rv0577 were generated in
BALB/c mice by s.c. injection of 1 mg purified Rv0577
proteins emulsified with equal volume of incomplete
Freund’s adjuvant (Sigma). The first immunization was car-
ried out with incomplete Freund’s adjuvant followed by 2
booster immunizations with the same procedure at 10-d
intervals. The antibody titers in the serum were determined
by ELISA after 2 wk postfinal immunization.
Generation and culture of DCs
Bone marrow cells isolated from C57BL/6 mice were lysed
with red blood cell (RBC) lysing buffer (ammonium chloride,
4.15 g/500 ml, and 0.01 M Tris-HCl buffer, pH 7.5	2) and
washed with RPMI 1640 medium. Obtained cells were plated
in 6-well culture plates (106 cells/ml, 3 ml/well) and cultured
at 37°C in the presence of 5% CO2 using RPMI 1640 medium
supplemented with 100 U/ml penicillin/streptomycin
(Lonza), 10% fetal bovine serum (Lonza), 50 
M mercapto-
ethanol (Lonza), 0.1 mM nonessential amino acid (Lonza), 1
mM sodium pyruvate (Sigma), 20 ng/ml GM-CSF, and 20
ng/ml IL-4. On d 6 or 7 of culture, nonadherent cells and
loosely adherent proliferating DC aggregates were harvested
for analysis or stimulation, or in some experiments they were
replated into 60-mm dishes (106 cells/ml, 5 ml/dish). On d 6,
80% of the nonadherent cells expressed CD11c. To obtain
highly purified populations for subsequent analyses, the DCs
were labeled with bead-conjugated anti-CD11c mAb (Miltenyi
Biotec, Bergisch Gladbach, Germany), followed by positive
selection on paramagnetic columns (LS columns; Miltenyi
Biotec) according to the manufacturer’s instructions. The
purity of the cell fraction selected was 95%.
Cytotoxicity analysis
The Rv0577 (10 
g/ml) was added to cultures of isolated
bone marrow-derived DCs (BMDCs) in 12-well plates
(0.5106 cells/ml). To investigate the cytotoxic effect of
Rv0577 on BMDCs, the cell-death pattern of BMDCs was
analyzed after treatment with 10 
g/ml Rv0577. After 24 h of
treatment, harvested DCs were washed with PBS and stained
by FITC-annexin V and propidium iodide (BD Biosciences).
Thereafter, cytotoxicity of DCs was analyzed by FACSCanto
flow cytometry (BD Biosciences).
Measurement of cytokines
A sandwich ELISA was used for detecting IL-6, IL-1, TNF-,
IFN-, IL-4, IL-2, IL-12p70, and IL-10 in culture supernatants,
as described previously (19). Assays of cytokines in culture
medium were performed as recommended by the manufac-
turers (eBioscience and BD Biosciences). The levels of cyto-
kines released into culture medium were determined by
measuring absorbance at 450 nm with a microplate reader.
Cytokine concentrations in the samples were calculated using
standard curves generated from recombinant cytokines, and
the results were expressed in picograms per milliliter.
Intracellular cytokine assays
Cells were first blocked with 10% (v/v) normal goat serum for
15 min at 4°C and then stained with FITC-conjugated
CD11c antibody for 30 min at 4°C. Cells stained with the
appropriate isotype-matched Ig were used as negative con-
trols. The cells were fixed and permeabilized with a Cytofix/
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Cytoperm kit (BD Biosciences) used according to the manu-
facturer’s instructions. Intracellular IL-12p70, IL-10, IL-2,
IL-4, and IFN- were detected with fluorescein-conjugated
antibodies (BD Biosciences) in a permeation buffer. The cells
were analyzed with a flow cytometry using the CellQuest (BD
Biosciences) program.
Analysis of the expression of surface molecules by flow
cytometry
On d 6, BMDCs were harvested, washed with PBS, and
resuspended in fluorescence-activated cell sorter washing
buffer (2% FBS and 0.1% sodium azide in PBS). The cells
were preincubated with 0.5% BSA in PBS for 30 min and
washing with PBS. The cells were stained with PE-conjugated
anti-H-2Kb (MHC class I), anti-I-Ab (MHC class II), anti-
CD80, and anti-CD86 along with FITC-conjugated anti-CD11c
for 45 min at 4°C. Cells were washed 3 times with PBS and
resuspended in 500 
l PBS. The fluorescence was measured
by flow cytometry, and the data were analyzed using Cell-
Quest data analysis software.
Ag uptake ability of BMDCs by Rv0577
BMDCs (2105 cell) were equilibrated at 37°C or 4°C for 45
min and then pulsed with fluorescein-conjugated dextran at a
concentration of 1 mg/ml. Cold staining buffer was added to
stop the reaction. The cells were washed three times, stained
with PE-conjugated anti-CD11c antibodies, and then analyzed
with the FACSCanto. Nonspecific binding of dextran to DCs
was determined by incubation of DCs with FITC-conjugated
dextran at 4°C, and the resulting background value was
subtracted from the specific binding values.
Confirmation of LPS-decontamination for Rv0577
To confirm the maturation of DCs induced by Rv0577 was not
due to contaminating endotoxins or LPS in the protein
preparations, the pretreatment with PmB (Sigma), heat-
denaturation, and digestion of proteinase K (Sigma) assays
were performed. DCs were preincubated with 50 
g/ml PmB
for 1 h at room temperature prior to treating with 100 ng/ml
LPS and 10 
g/ml Rv0577. For heat denaturation, LPS or
Rv0577 was incubated at 100°C for 1 h. For digestion of
proteinase K, LPS or Rv0577 was digested for 1 h at 37°C with
soluble proteinase K at the concentration of 10 
g/ml,
followed by heating for 15 min at 100°C to deactivate the
enzyme, and subsequently was added to BMDC cultures. After
24 h, TNF- and IL-6 levels in the supernatant of BMDCs were
analyzed using ELISA.
Confocal laser scanning microscopy
DCs were plated overnight on poly-l-lysine-coated glass cov-
erslips. After treatment with Rv0577, cells were fixed in 4%
paraformaldehyde, permeabilized in 0.1% Triton X-100, and
then blocked with 2% BSA in PBS containing 0.1% Tween-20
(PBS/T) for 2 h before being incubated with 2% BSA in
PBS/T containing anti-Rv0577 antibody for 2 h at room
temperature. After washing with PBS/T, the cells were rein-
cubated with Cy-3 conjugated secondary antibody in the dark
room for 1 h, and then were stained with 1 
g/ml of DAPI for
10 min at room temperature. Cell morphology and fluores-
cence intensity were observed using a confocal laser scanning
microscope (Zeiss LSM510 Meta; Carl Zeiss Ltd, Welwyn
Garden City, UK). Images were acquired using the LSM510
Meta software and processed using the LSM image examiner.
Immunoprecipitation
DCs (1107) were incubated with 10 
g/ml Rv0577 for 6 h,
and cell pellets were lysed with lysis buffer (10 mM Tris-HCl,
pH 7.4; 1% Nonidet P-40; 0.25% sodium deoxycolate; 150
mM NaCl; 1 mM EDTA; 1 mM PMSF; 1 
g/ml each apro-
tinin, leupeptin, and pepstatin; 1 mM Na3VO4; and 1 mM
NaF). To avoid nonspecific binding, the cell lysates were
precleared by adding 50 
l of normal serum (Santa Cruz
Biotechnology) and 100 
l of 50% protein A or G sepharose
bead slurry (Invitrogen) to 1 mg of cell lysates. After the 2 h
incubation at 4°C, the mixture of bead and cell lysates was
centrifuged at 10,000 g for 5 min at 4°C, and the supernatant
was collected for the subsequent experiment. Rv0577 (His)-,
TLR2-, and TLR4-associated proteins were immunoprecipi-
tated by incubation with protein A or G Sepharose for 24 h at
4°C after incubation with anti-rat IgG as control Ab for
anti-TLR2 and anti-TLR4, anti-mouse IgG as control Ab for
anti-Rv0577 (His) for 1 h at 4°C. The beads were harvested,
washed, and boiled in 5 sample buffer for 5 min. The
proteins were separated on 10% SDS-PAGE followed by
transfer of proteins to polyvinylidene difluoride membrane
(Millipore, Billerica, MA, USA). The membranes were further
probed with anti-TLR2, anti-TLR4, and anti-His Abs as indi-
cated.
Immunoblotting analysis
After stimulation with 10 
g/ml Rv0577, DCs were lysed in
100 
l lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150
mM NaCl, 1% Triton-X100, 1 mM EDTA, 50 mM NaF, 30 mM
Na4PO7, 1 mM phenylmethanesulfonyl fluoride, 2 
g/ml
aprotinin, and 1 mM pervanadate. Whole-cell lysate samples
were resolved on SDS-polyacrylamide gels and then trans-
ferred onto a nitrocellulose membrane. The membranes were
blocked in 5% skim milk and incubated with the antibody for
2 h, followed by incubation with HRP-conjugated secondary
Abs for 1 h at room temperature. Epitopes on target proteins
including MAPKs and NF-B recognized specifically by Abs
were visualized by using the ECL advance kit (GE Healthcare,
Little Chalfont, UK).
Nuclear extract preparation
Nuclear extracts from cells were prepared as follows. DCs
were treated with 100 
l lysis buffer [10 mM HEPES, pH 7.9;
10 mM KCl; 0.1 mM EDTA; 0.5% Nonidet P-40; 1 mM
dithioreitol (DTT); and 0.5 mM PMSF] on ice for 10 min.
Postcentrifugation at 4000 rpm for 5 min, the pellet was
resuspended in 100 
l extraction buffer (20 mM HEPES, pH
7.9; 400 mM NaCl; 1 mM EDTA; 1 mM DTT; and 1 mM
PMSF) and incubated on ice for 30 min. Postcentrifugation at
12,000 rpm for 10 min, the supernatant containing nuclear
extracts was collected and stored at 80°C until required.
Treatment of DCs with pharmacological inhibitors of
signaling pathways
All the pharmacological inhibitors were purchased from
Calbiochem. Dimethyl sulfoxide (DMSO; Sigma) was added
to cultures at 0.1% (v/v) as a solvent control. DCs were
washed with PBS and pretreated with inhibitors in RPMI 1640
medium containing glutamine for 1 h prior to treatment with
Rv0577 for 24 h. Inhibitors were used at following concentra-
tions: U0126, 10 
M; SB203580, 20 
M; SP600125, 10 
M;
and Bay11-7082, 20 
M. In all experiments with inhibitors, a
tested concentration was used after careful titration experi-
ments assessing the viability of the DCs using MTT assay.
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MLR
Responder T cells, which participate in naive T-cell reactions,
were isolated using a MACS column (Miltenyi Biotec) from
total mononuclear cells prepared from BALB/c mice. Both
OVA-specific CD8 and CD4 T cells, responders, were
obtained from splenocytes of OT-1 and OT-2 mice, respec-
tively. These T cells were stained with 1 
M carboxyfluores-
cein diacetate succinimidyl ester (CFSE; Invitrogen) as de-
scribed previously (20). DCs (2105 cells/well) treated with
OVA peptide in the presence of 10 
g/ml of Rv0577 for 24 h
were cocultured with CFSE-stained CD8 and CD4 T cells
(2106) at DC:T-cell ratios of 1:10. On 3 or 4 d of coculture,
T cells were stained with PerCP-cy5.5-conjugated anti-CD4
mAb, PE-cy5-conjugated anti-CD4 mAb, PE-cy5-conjugated
anti-CD8 mAb, Alexa647-conjugated anti-CCR3 mAb, or
PE-conjugated anti-CXCR3 mAb and analyzed by flow cytom-
eter. Supernatants were harvested, and the production of
IFN-, IL-2, and IL-4 was measured by ELISA.
Analysis of the activation of effector/memory T cells
As explained above, responder T cells, which participate in
allogeneic T-cell reactions, were isolated using a MACS
column (Miltenyi Biotec) from total mononuclear cells
prepared from M. tuberculosis-infected BALB/c mice. Stain-
ing with APC-conjugated anti-CD3 mAb (BD Biosciences)
revealed that the preparation consisted mainly of CD3
cells (95%). DCs (2105 cells/well) prepared from wild-
type (WT), TLR2/, and TLR4/ C57BL/6 mice were
treated with Rv0577 for 24 h followed by extensive washing
and were cocultured with 2  106 responder allogeneic T
cells (M. tuberculosis-infected T cells) at DC:T cell ratios of
1:10. On d 4 of coculture, the cells were stained with
PerCP-cy5.5-conjugated anti-CD4 mAb, PerCP-cy5.5-con-
jugated anti-CD8 mAb, FITC-conjugated anti-CD62L
mAb, and PE-conjugated anti-CD44 mAb, and analyzed by
flow cytometer.
Statistical analysis
All experiments were repeated 3 times with consistent
results. The levels of significance for comparison between
samples were determined by Tukey’s multiple comparison
test distribution using statistical software (Prism 4.03; Graph-
Pad, San Diego, CA, USA). The data in the graphs are
expressed as means 	 se. Values of P  0.05were considered
to be statistically significant.
RESULTS
Purification of recombinant Rv0577 protein and
cytotoxicity
Rv0577 is an M. tuberculosis complex-restricted se-
creted protein involved in the methylglyoxal detoxi-
fication pathway (14). However, the immunological
contribution of Rv0577, especially the effect on
the maturation and functions of DCs, remains un-
known.
Recombinant Rv0577 protein was therefore pro-
duced and characterized. The purity of Rv0577 was
first assessed by SDS-PAGE and Western blot analysis.
The purified recombinant Rv0577 protein had a
molecular mass of 32 kDa (Supplemental Fig. S1A).
Endotoxin content was measured by an LAL assay
and was 15 pg/ml (0.1 UE/ml) in Rv0577 prep-
arations. Rv0577 had 96% purity when 20 
g of the
protein preparation was stained with silver nitrate
(data not shown). We next examined the Rv0577
protein-induced cytotoxicity in DCs by treating cells
with 10 
g/ml Rv0577 for 24 h, then staining with
anti-CD11c, annexin V, and propidium iodide to
assess cell viability. As shown in Supplemental Fig.
Figure 1. Cytokine production by Rv0577 protein-treated DCs.
DCs were generated by stimulating immature DCs with 100
ng/ml LPS, or 5 or 10 
g/ml Rv0577 for 24 h. A–E) Amounts of
TNF- (A), IL-6 (B), IL-1 (C), IL-10 (D), and IL-12p70 (E) in
the culture supernatant was measured by ELISA. All data are
expressed as means 	 sd (n3). n.s., not significant. *P  0.05,
**P  0.01, ***P  0.001 vs. controls. F) Dot plots of intracel-
lular IL-12p70 and IL-10 in CD11c DCs. Percentage of positive
cells is shown in each panel.
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S1B, up to 10 
g/ml of Rv0577 protein displayed no
cellular toxicity against DCs. Notably, this suggests
that recombinant Rv0577 protein was not cytotoxic to
DCs and when used in concentrations 10 
g/ml
would not contain significant amounts of endotoxin
to interfere with our studies.
Rv0577 induces the secretion of proinflammatory
cytokines by DCs toward a Th1 type immune
response
Previous studies have reported that DC-derived cyto-
kines play a critical role in the polarization of T cells
and in mediating inflammatory responses (21). We
therefore analyzed whether Rv0577-mediated matura-
tion of DCs was coupled with the secretion of pro- or
anti-inflammatory cytokines by stimulating DCs with
various concentrations of Rv0577 (5–10 
g/ml). As
demonstrated in Fig. 1A–C, Rv0577 significantly stimu-
lated DCs to secrete high levels of TNF-, IL-6, and
IL-1, whereas untreated DCs secreted negligible
amounts of these cytokines. We then investigated the
production of IL-12p70 and IL-10, which have an
important effect on the development of T cell-medi-
ated immune responses. Unlike LPS, Rv0577 signifi-
cantly induced the secretion of IL-12p70, but not IL-10
(Fig. 1D, E). We also analyzed the production of
intracellular IL-12p70 and IL-10 in Rv0577-treated DCs.
As shown in Fig. 1F, DCs treated with Rv0577 increased
the percentage of IL-12p70-positive cells compared to
the results obtained for untreated DCs, while no
change was found in IL-10-positive cells. These results
strongly suggest that Rv0577 induces the secretion of
proinflammatory cytokines from DCs and these
Rv0577-matured DCs may promote a Th1 type immune
response.
Rv0577 induces maturation of DCs
Maturation of DCs plays a major role in mediating
immune responses to mycobacteria (4). Therefore,
to investigate whether Rv0577 induces DC matura-
tion, we first measured the expression of DC matu-
ration markers such as CD80, CD86, and MHC classes
I and II. BMDCs were cultured for 24 h in the
presence of 5 or 10 
g/ml Rv0577 and analyzed for
the expression of surface markers. LPS was used as a
positive control. As shown in Fig. 2, Rv0577 en-
hanced the expression of costimulatory molecules
such as CD80 and CD86, and cell surface markers
such as MHC classes I and II at concentrations of 5
Figure 2. Rv0577 induces the expression of costimulatory and MHC molecules on DCs in a dose-dependent manner. Immature
DCs (1106 cells/ml) were cultured with GM-CSF and IL-4 alone (control) or GM-CSF, IL-4, or 5 or 10 
g/ml Rv0577 or
GM-CSF, IL-4, or 100 ng/ml LPS for 24 h and analyzed for the expression of surface markers by 2-color flow cytometry. Cells
were gated on CD11c cells. DCs were stained with anti-CD80, anti-CD86, or anti-MHC class I or anti-MHC class II. Percentage
of positive cells is shown for each panel. Bar graphs show mean 	 se percentage of each surface molecule on CD11c cells for
3 independent experiments*P  0.05, **P  0.01, ***P  0.001 vs. controls.
Figure 3. Rv0577 binds to TLR2, but not TLR4. A) BMDCs
derived from WT, TLR2/, and TLR4/ mice were
treated with Rv0577 (10 
g/ml) for 1 h and stained with
an Alexa488-conjugated anti-His mAb. Percentage of
positive cells is shown in each panel. B) Bar graphs show
mean 	 se percentage of Rv0577-Alexa488 in CD11c
cells from 3 independent experiments. ***P  0.001.
C) Immunoprecipitation (IP) with anti-His, anti-TLR2,
or anti-TLR4 antibodies and immunoblotting (IB) with
anti-His, anti-TLR2, or -TLR4 antibodies. DCs were
treated with Rv0577 (10 
g/ml) for 6 h. Cells were
harvested, and cell lysates were immunoprecipitated
with anti-rat IgG, anti-mouse IgG, anti-His, anti-TLR2, or
anti-TLR4; then proteins were visualized by immunoblotting with anti-His, anti-TLR2, or anti-TLR4 Abs. Total cell lysate
was used as an input control. D) Fluorescence intensities of anti-Rv0577 bound to Rv0577-treated DCs. DCs derived from
WT, TLR2/, and TLR4/ mice were treated with Rv0577 (10 
g/ml) for 1 h, fixed, and stained with DAPI and a
Cy3-conjugated anti-Rv0577 antibody. Scale bar  10 
m.
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Figure 4. Rv0577 induces the activation of DCs via the interaction with TLR2. A) Histograms showing CD86 or MHCII
expression on Rv0577-treated CD11c-gated DCs derived from WT, TLR2/, and TLR4/ mice. DCs derived from WT,
TLR2/, and TLR4/ mice were treated with Rv0577 (10 
g/ml) for 24 h. Percentage of positive cells is shown for each
panel. Bar graphs show mean 	 se percentage for each surface molecule on CD11c cells in 3 independent experiments.
(continued on next page)
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and 10 
g/ml, suggesting that Rv0577 efficiently
induces DC maturation.
Rv0577 reduces the endocytic activity of DCs
The expression of surface molecules and changes in
IL-12 production show that exposure to Rv0577 leads to
profound induction of the phenotypic maturation of
DCs. In this study, we investigated the role of Rv0577 in
the regulation of DC endocytic activity. To test whether
Rv0577 protein-stimulated DCs had the reduced endo-
cytic activity, we exposed DCs to Rv0577 in the presence
of dextran-FITC and assessed the percentage of double-
positive cells (CD11c and dextran-FITC-positive). As
shown in Supplemental Fig. S2, a much lower percent-
age of active cells was present in LPS-treated DCs than
in untreated DCs. In addition, the same was true of
Rv0577-treated DCs when compared to untreated DCs. Our
results showed that Rv0577-treated DCs had reduced endo-
cytic activity, indicating more functional maturity.
Confirmation of endotoxin-free purified Rv0577
preparations
To ensure that Rv0577-induced DC maturation was not
due to endotoxin or LPS contamination, the purified
Rv0577 preparations were passed through a PmB-aga-
rose column. Furthermore, we assessed LPS contami-
nation by treatment with proteinase K or heat denatur-
ation, which abrogated the ability of Rv0577 to trigger
DC maturation (Supplemental Fig. S3A, B). PmB treat-
ment did not affect the viability of Rv0577, whereas that
of LPS was significantly inhibited by PmB (Supplemen-
tal Fig. S3C). These results confirmed that DC matura-
tion was in fact induced by intact Rv0577 and not by
contaminating LPS.
Rv0577 interacts with TLR2 and induced DC maturation
Pattern recognition receptors, such as TLRs, have the
ability to recognize pathogen-associated molecular pat-
terns from whole mycobacterial cells or mycobacterial
cell wall components (7). Thus, we examined whether
Rv0577 could be recognized by, and act through, TLRs
in DCs. To identify TLRs on DCs that interact with
Rv0577, WT, TLR2/, and TLR4/ DCs were stimu-
lated with Rv0577; then Rv0577 on the cell surface was
detected with an Alexa488-conjugated anti-Rv0577
polyclonal Ab (Fig. 3A). Anti-Rv0577 bound to the cell
surface of WT and TLR4/ DCs but not TLR2/ DCs
(Fig. 3B). To confirm the interaction between Rv0577
and TLR, we performed immunoprecipitation studies
with TLR2 or TLR4 and Rv0577 in DCs. Rv0577 bound
to TLR2 but not TLR4 (Fig. 3C). This observation was
also confirmed by confocal microscopy. Interestingly,
we found that Rv0577 interacts preferentially with WT
and TLR4/ DCs but not TLR2/ DCs (Fig. 3D).
To test the ability of Rv0577 to activate DCs via TLR2,
we measured the expression of surface molecules and
proinflammatory cytokine production in Rv0577-treated
WT, TLR2/, and TLR4/ DCs. The expression of
surface molecules (Fig. 4A) and proinflammatory cyto-
kine secretion (Fig. 4B) were enhanced in WT or
TLR4/ DCs by Rv0577. In contrast, these effects were
strongly diminished in TLR2/ DCs, indicating that
Rv0577 is an agonist for TLR2 in DCs.
TLRs are critical in provoking innate immune re-
sponses through the activation of signaling cascades via
TIR domain-containing adaptors, such as MyD88 and
TRIF (22). MyD88 is common to all the TLRs, whereas
TRIF is essential for TLR4-mediated activation of the
MyD88-independent signaling pathway (22). Thus,
MyD88 and TRIF play a potential role in the control of
TLR2- and TLR4-mediated signaling pathways. To in-
vestigate the importance of the MyD88- and TRIF-
dependent pathways in Rv0577-induced cytokine pro-
duction by DCs, we compared DC-based cytokine
production in WT, MyD88/, and TRIF-deficient
mice. Rv0577-induced production of TNF-, IL-6, and
IL-1 was significantly reduced in the absence of
MyD88, whereas this effect was not observed in the
absence of TRIF (Fig. 4C). These findings clearly
demonstrated that Rv0577 induced DC maturation in a
TLR2-dependent manner, causing increased expres-
sion of cell-surface molecules and proinflammatory
cytokines.
Expression of the NF-B and MAPK pathways in
Rv0577 protein-induced maturation of DCs
NF-B and MAPKs are critical factors mediating cellular
responses such as innate immunity, cellular prolifera-
tion, and survival, and recent studies have suggested
that NF-B and MAPKs are essential for the maturation
of DCs (22, 23). We therefore examined the activation
of NF-B and MAPKs in response to Rv0577. DCs were
stimulated with Rv0577 recombinant protein at a con-
centration of 10 
g/ml, and the phosphorylation of
MAPKs (including ERK1/2, p38, and JNK), the phos-
phorylation/degradation of IB-, and the nuclear
translocation of p65 were analyzed over time (Fig. 5).
As shown in Fig. 5A, the Rv0577 triggered the phos-
phorylation of MAPKs, such as ERK1/2, p38, and JNK.
In addition, we found that the Rv0577 induced the
phosphorylation and degradation of IB- and nuclear
translocation of p65 from cytosol (Fig. 5B, C). These results
***P  0.001. B) DCs derived from WT, TLR2/, and TLR4/ mice were treated with Rv0577 or LPS for 24 h. TNF-, IL-6,
or IL-1 production in Rv0577- or LPS-treated DCs derived from WT, TLR2/, and TLR4/ mice was measured by ELISA.
C) DCs derived from WT, MyD88/, and TRIF/ mice were treated with Rv0577 (10 
g/ml) and Pam3 (100 ng/ml) for 24
h. TNF-, IL-6, or IL-1 production in Rv0577- or Pam3-treated DCs derived from WT, MyD88/, and TRIF/ mice was
measured by ELISA. All data are expressed as means 	 sd (n3). ***P  0.001.
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suggest that Rv0577 protein-induced DC activation might be
mediated by both the NF-B and MAPK pathways.
Rv0577 induces the production of proinflammatory
cytokines and the expression of costimulatory
molecules through NF-B and MAPKs
Previous studies have demonstrated that activation of the
NF-B and MAPK signaling pathways plays a crucial role
in the maturation of DCs induced by mycobacterial Ags
(13, 24). The molecular mechanisms involved in the
regulation of DCs by Rv0577 protein, however, are not yet
fully understood. Thus, to elucidate the functional roles
of these kinases in the activation of DCs induced by
Rv0577, we used highly specific kinase inhibitors and
measured Rv0577-induced proinflammatory cytokine pro-
duction and costimulatory molecule expression. The cells
were pretreated with a p38 inhibitor (SB203580), an
ERK1/2 inhibitor (U0126), a JNK inhibitor (SP600125),
or NF-B inhibitor (Bay 11-0782) for 1 h before being
exposed to Rv0577. Notably, we found that these pharma-
cological inhibitors significantly abrogated Rv0577-induced
expression of the costimulatory molecules on the surface of
DCs (Fig. 6A), and the production of proinflammatory
cytokines (Fig. 6B). From these findings, we suggest that the
NF-B and MAPK signaling pathways are essential for the
production of proinflammatory cytokines and the expres-
sion of DC maturation markers induced by Rv0577.
Rv0577 protein-stimulated DCs induce naive T-cell
proliferation
Increased expression of the costimulatory molecules,
CD80 and CD86, along with MHC classes I and II, on DCs
promotes their interaction with and activation to T cells.
To precisely characterize Rv0577 activity on DC and T-cell
interactions, we performed a syngeneic MLR assay using
OT-I TCR transgenic CD8 T cells and OT-II TCR
transgenic CD4 T cells. Transgenic CFSE-labeled OVA-
specific CD4 and CD8 T cells cocultured with Rv0577-
treated DCs, pulsed with OVA257–264 (Fig. 7A) or OVA323–339
(Fig. 7B) and proliferated to a significantly greater extent
than the same T cells cocultured with DCs without Rv0577
treatment, but pulsed with OVA257–264 or OVA323–339.
Furthermore, naive CD4 and CD8 T cells primed with
Rv0577-treated DCs produced significantly (P0.05–
0.01) higher IFN- and IL-2 levels than those with un-
treated DCs, whereas the comparable level of IL-4 secre-
tion was detected regardless of Rv0577 stimulation (Fig.
7C). We then investigated the expression of chemokine
receptor CXCR3 and CCR3, which are associated with
T-cell polarization, in CD4 T cells using flow cytometry.
Figure 5. DC maturation triggered by Rv0577 involves activation of MAPKs and NF-B.
A–C) DCs were treated with 10 
g/ml Rv0577 protein, and protein expression is shown
over time. Cell lysates were subjected to SDS-PAGE, and immunoblot analysis was
performed using each specific antibody to phospho-p38 (p-p38), p38, phospho-ERK1/2
(p-ERK1/2), ERK1/2, phospho-JNK (p-JNK), and JNK (A); phosphor-IB- (p-IB-) and
IB- (B); and p65 NF-B (C). -Actin (B) and lamin B (C) were used as loading controls
for cytosolic and nuclear fractions, respectively. Relative band intensity of each protein is
expressed as a percentage compared to the value of untreated controls. Results shown are typical of 3 experiments done under
each condition. Data are shown as means 	 sd (n3), *P  0.05, **P  0.01, ***P  0.001 vs. untreated DCs.
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CXCR3 is known to be expressed at a high level on Th1
cells, whereas Th2 cells up-regulate the expression of
CCR3 (25). As shown in Fig. 7D, CD4 T cells cocultured
with Rv0577-treated DCs, pulsed with OVA323–339 showed
a significant increase in the expression of CXCR3 com-
pared to those cocultured with DCs pulsed with OVA323–339
only, whereas no alteration in the expression of CCR3
by Rv0577 was investigated. These results suggest that
the Rv0577-treated DCs direct naive T-cell prolifera-
tions toward a Th1 phenotype.
Rv0577 induces the development of effector/memory
T cells via TLR2-mediated DC activation
To assess whether the maturation of DCs by Rv0577 is
reflected in their ability to specifically stimulate CD4 and
CD8 T cells from M. tuberculosis-infected mice, we ana-
lyzed the surface expression of CD62L and CD44 on
CD4 and CD8 splenic T cells using flow cytometry.
Naive T cells were previously reported to express a
CD62LhighCD44low phenotype, whereas effector/memory
T cells exhibit a CD44highCD62Llow phenotype (26). CD4
and CD8 splenic T cells from M. tuberculosis-infected
mice were cocultured with Rv0577-treated DCs derived
from WT, TLR2/, or TLR4/ mice. The Rv0577-
treated WT and TLR4/ DCs specifically induced the
formation of effector/memory T cells by displaying
significantly down-regulated CD62L and up-regulated
CD44 expression in CD4 and CD8 splenic T cells
from M. tuberculosis-infected mice compared to control
DCs, Pam3-treated DCs, and LPS-treated DCs, while
such an effect of Rv0577 was abrogated in TLR2/ DCs
(Fig. 8A). In addition, the percentages of CD4-IFN-/
CD4-IL-2 and CD8-IFN-/CD8-IL-2 double-positive
cells among T cells cocultured with Rv0577-WT or
TLR4/ DCs were higher than that of those cocul-
tured with untreated DCs, Pam3-pulsed DCs, or LPS-
pulsed DCs, whereas the elevation of theses cytokines
was not observed in T cells cocultured with Rv0577-
treated TLR2/ DCs (Fig. 8B). In addition, IL-4
expression of CD4 T cells among T cells treated with
Rv0577-pulsed DCs, Pam3-pulsed DCs, or LPS-pulsed
DCs remained at baseline levels (Fig. 8B). These data
suggest that Rv0577-mediated DC activation induces
the development of effector/memory T cells in M.
tuberculosis infection in a TLR2-dependent manner.
DISCUSSION
Rv0577, also known as CFP32, is one of the major
culture filtrate (CF) proteins that have emerged as
Figure 6. Involvement of the ERK1/2, p38, and JNK pathways in Rv0577 protein-induced
maturation of DCs. DCs were treated with pharmacological inhibitors of p38 (SB203580, 20

M), ERK1/2 (U0126, 10 
M), JNK (SP600125, 20 
M), NF-B (Bay11-7082, 20 
M), or
DMSO (vehicle control) for 1 h prior to treatment with 5 
g/ml Rv0577 for 24 h. A) Cells
were gated to include CD11c cells. DCs were stained with anti-CD80 and anti-CD86.
Expression of CD80 and CD86 was analyzed by flow cytometry. Bar graphs show mean 	 se percentage of each surface
molecule on CD11c cells from 3 separate experiments. B) Amounts of TNF-, IL-6, and IL-1 in the culture medium were
measured by ELISA. Values are means 	 se from 3 independent experiments. *P  0.05, **P  0.01, ***P  0.001 vs.
Rv0577-treated controls.
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Figure 7. Rv0577 protein-treated DCs stimulate T cells to produce Th1 cytokines. A, B) Transgenic OVA-specific CD8 T cells
and transgenic OVA-specific CD4 T cells were isolated, stained with CFSE, and cocultured for 96 h with DCs treated with
Rv0577 (10 
g/ml) or LPS (100 ng/ml), then pulsed with OVA257–264 (1 
g/ml) for OVA-specific CD8
 T cells (A) or
OVA323–339 (1 
g/ml) for OVA-specific CD4
 T cells (B). T cells only and T cells cocultured with untreated DCs served as
controls. Proliferation of OT-I (A) and OT-II (B) T cells was then assessed by flow cytometry. C) Culture supernatants
obtained from experiments in A and B were harvested after 24 h, and IFN-, IL-2, and IL-4 were measured by ELISA. D)
(continued on next page)
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potential candidates for the diagnosis and drug target-
ing of TB (14). The gene encoding Rv0577 is found
exclusively in the M. tuberculosis complex. Unlike other
CF proteins, such as 85 Ag complex, Rv0577 is uniquely
present in members of the M. tuberculosis complex and
has not been identified in environmental mycobacteria
(14). Furthermore, transfer of the rv0577 gene into
Mycobacterium smegmatis has recently been demon-
strated by Andreu et al. (27) to confer the virulence-
related neutral red character typical of virulent myco-
bacteria, suggesting an association of this gene with
virulence. In addition, Rv0577 levels in the lungs of
patients with active TB have been positively correlated
with the progression of the disease (14). Moreover,
Bertholet et al. (28) reported that Rv0577 provided a
partial protection as a T cell Ag against challenge with
M. tuberculosis in the mouse model. Recent research on
the proteomic analysis in exosomes from M. tuberculosis-
infected J774 cells also demonstrated that Rv0577 ex-
isted in exosomes as a highly antigenic protein (29).
These observations suggest that Rv0577 may play a role
in TB pathogenesis and likely interacts with the im-
mune system. From this perspective, identification and
characterization of novel Ags of M. tuberculosis includ-
ing Rv0577 that interact with host immune responses is
an essential step in the development of new drugs and
effective vaccines against TB.
Host immune responses are generally sufficient to
contain TB infection and many of the cell wall-associ-
ated or secreted Ags of pathogenic mycobacteria are
targets of host immune responses (2, 3). Among the
host immune cells, DCs are principal mediators of
initiation as well as activation of host immune responses
to TB infection; thus, they are essential for the contain-
ment of M. tuberculosis infections by inducing cellular
immune responses to mycobacteria (4). Recent studies
have examined the interaction of DCs with M. tubercu-
losis Ags, and some, such as Rv0754 and Rv0978c, were
found to induce maturation and activation of DCs by
regulating the NF-B and MAPK signaling pathways,
enhancing the ability of DCs to stimulate CD4 T cells
(11). In addition, M. tuberculosis Ags, such as Rv1196
and Rv1917c, were reported to strongly induce the
secretion of IL-10, known to favor and drive Th2
immune response (13, 30). Although many M. tubercu-
losis Ags have been discovered, little is known about M.
tuberculosis Ags that induce Th1-polarized immune re-
sponses via DC maturation. Recently, the M. tuberculosis
protein Rv0577 was detected in individuals infected
with M. tuberculosis (14), and previous work has re-
ported the development of specific Rv0577 serum anti-
body-capture ELISAs for TB diagnosis (31). Little is
known, however, about the functional role of M. tuber-
culosis Rv0577 in the biology of M. tuberculosis. In this
study, we show that M. tuberculosis Rv0577 induces DC
maturation by augmenting the expression of CD80,
CD86, and MHC class I and MHC class II molecules and
produces markedly higher levels of proinflammatory
cytokines, such as TNF-, IL-6, and IL-1. Furthermore,
Rv0577 was found to significantly induce the secretion
of IL-12p70, a Th1-polarizing cytokine, but not IL-10.
IL-12 was previously reported to mediate the expression
of proinflammatory cytokines, such as TNF-, IL-1,
and IL-6, in DCs (32), and when secreted by APCs is
known to induce the secretion of IFN- from T cells
and to play a critical role in driving Thl immune
responses (33). Thus, our findings indicate that Rv0577
contributes to Th1 polarization of the immune re-
sponse via DC maturation.
Cell-surface interactions are one of the most impor-
tant events for the initiation of biological responses to
extracellular stimuli. Among various cell-surface recep-
tors, TLR2 is crucial in both the innate and adaptive
immune responses of a host to microbial pathogens (8)
and is known to play a pivotal role in the activation of
inflammatory immune responses by M. tuberculosis Ags
(34). M. tuberculosis Ags, such as glycolipids and lipo-
proteins, were shown to stimulate macrophage and DC
activation through TLR2, thus stimulating both CD4
and CD8 T lymphocytes (35). Rv1818c was shown to
interact directly with TLR2, thereby mediating apopto-
sis and cytokine secretion (36). Rv0978c and Rv0754
were also shown to interact with TLR2, prompting
maturation and activation of DCs (11). In addition,
lipomannan (LM) from several mycobacterial species
was found to induce macrophage activation, which was
characterized by TNF- and nitric oxide secretion
through TLR2 (37). These findings suggest that TLR2
may play a significant role in regulating the cellular
immune responses of M. tuberculosis. Thus, identifica-
tion of novel TLR2 agonists is needed for use as
adjuvants in infectious disease control and in the
development of credible vaccine candidates. Although
several M. tuberculosis Ags have been identified as TLR2
agonists and are known to regulate APC activation by
modulating TLR2-mediated signaling, the underlying
mechanisms of how the novel M. tuberculosis Rv0577
interacts with the cell surface are not understood. Here
we show, for the first time, that Rv0577 directly interacts
with cell surface TLR2 and induces DC maturation in a
TLR2-dependent manner. In addition, we also show
that Rv0577 significantly increases the expression of
surface molecules and proinflammatory cytokine secre-
tion by activation of the MAPK and NF-B pathways in
DCs under MyD88-dependent signaling pathways.
Thus, our findings indicate that Rv0577 is an agonist
for TLR2 and that MyD88-mediated signaling is essen-
tial for an optimal, Rv0577-induced cytokine response
by DCs. MyD88 was previously shown to act as an
adaptor molecule essential for signaling of Ags via the
Splenocytes were stained with anti-CXCR3 mAb or anti-CCR3 mAb. Percentage of positive cells is shown for each panel.
Histograms and bar graphs show CXCR3CCR3 T cells in the OVA-specific CD4 T cells. Values are means 	 se from 3
independent experiments. n.s., not significant. *P  0.05, **P  0.01, ***P  0.001 vs. corresponding controls.
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Figure 8. Rv0577 protein-stimulated DCs induce the effec-
tor/memory T cell proliferation via TLR2 signaling. A) WT,
TLR2/, and TLR4/ DCs were cultured with 10 
g/ml
Rv0577 for 24 h. Rv0577-treated WT, TLR2/, and
TLR4/ DCs were then washed and cocultured with allo-
geneic T cells at DC to T-cell ratios of 1:10 for 3 d.
Splenocytes were stained with anti-CD4, anti-CD8 mAb,
anti-CD62L, and anti-CD44 mAbs. Histograms and bar graphs show CD44CD62L T cells in the spleen. Bar graphs show
mean	 se percentages of CD4/CD44CD62L and CD8/CD44CD62L T cells from 3 independent experiments. n.s.,
not significant. **P  0.01, ***P  0.001 vs. untreated DCs. B) IFN-, IL-2, or IL-4 expression in CD3/CD4 and
CD3/CD8 cells was analyzed in T cells cocultured with Rv0577-pulsed DCs, Pam3-pulsed DCs, or LPS-pulsed DCs by
intracellular IFN-, IL-2, or IL-4 staining. Percentages of double-positive cells among the T cells are indicated in the top right
corner; results are representative of 3 independent experiments.
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TLR family (8). Furthermore, signaling through
MyD88 was reported to play a crucial role in host
resistance associated with the regulation of mycobacte-
rial-induced cytokine production (38). Others have
shown that MyD88-deficient APCs, like macrophages
and DCs, display a marked reduction in the synthesis of
IL-12, TNF-, and nitric oxide when exposed to M.
tuberculosis (39).
An important finding of this study was that the
Rv0577 expressed in E. coli mediated TLR2 signaling. In
general, TLR2 has been well documented to be recog-
nized by lipidated Ags, including mycobacterial lipo-
proteins, such as LprA (Rv1280c) and LpqH (Rv3763),
and glycolipids, such as phosphatidyl-(myo)-inositol
mannosides (PIMs), lipomannans (LMs), lipoarabino-
mannans (LAMs), and inositol phosphate-capped
LAMs (PI-LAMs). Although Escherichia coli lacks post-
translational modifications such as glycosylation and
acylation, several mycobacterial proteins work as TLR2
agonists. For example, PE_PGRS33 expressed in E. coli
triggers apoptosis in macrophages by directly interact-
ing with TLR2 (36), and M. tuberculosis heat shock
protein 60 expressed in E. coli modulates immune
responses by interacting with TLR2 on macrophages
(40). Another study showed that early secreted Ag
ESAT-6 of M. tuberculosis expressed in E. coli blocked
TLR signaling by direct interaction with TLR2 (24).
Originally, M. tuberculosis LprG (Rv1411c) was known to
require acylation to reflect TLR2 agonist activity (34)
but nonacylated LprG retained TLR2 activity, suggest-
ing that certain proteins of M. tuberculosis do not
require lipidation for their TLR2 activity (41). Thus,
the acylation of Rv0577 is not required for TLR2
activity.
Another significant finding of our work was that
Rv0577 induced Th1-polarized immune responses,
which are thought to be critical to host protection
against M. tuberculosis infection. Although TLR2-medi-
ated immune responses of cell wall fractions and lipo-
proteins are essential for the induction of a protective
immune response to mycobacteria (42), several TLR2
agonists discovered in M. tuberculosis, including PE/PPE
family proteins, LprA, and LprG, contribute to escape
of the bacterium from host defenses. Rv1917c of M.
tuberculosis (PPE34), for example, induces selective mat-
uration of human DCs toward Th2 immune responses,
with increased levels of IL-10 and lipoproteins (includ-
ing LprA and LprG) and inhibits MHC II-mediated Ag
processing of macrophages, resulting in a decrease in
IFN- production (13).
T lymphocytes play a critical role in the control of a
protective immune response in M. tuberculosis infection
(43). Under optimal Ag stimulation, DCs first take up
Ags and then travel to the lymph nodes where they
present processed Ags to naive T cells. These naive T
cells are stimulated to proliferate and differentiate into
functional effector and memory T cells, a subset of
antigen-specific T cells (44). These cells generally do
not show direct action during an infection; instead,
they enable the body to react quickly and control a
recognized pathogen if encountered again (44). Thus,
the M. tuberculosis vaccine likely acts to affect the quality
and quantity of memory T cells.
Recently, several studies have revealed that M. tuber-
culosis Ags induce the activation of CD4 and CD8 T
cells through TLR-mediated DC activation. This is
thought to lead to protective immunity against M.
tuberculosis by triggering IFN- production, which plays
a particularly important role in the activation of anti-
gen-presenting cells in CD4 and CD8 T cells (12,
13). Based on this, CD4 and CD8 T cells have been
suggested to play a protective role in immune responses
against infection. Notably, we showed that Rv0577
enhances the ability of DCs to stimulate naive T cells
and that Rv0577-matured DCs trigger IFN- and IL-2
production in CD4 and CD8 T cells. In addition, we
also found that Rv0577-treated DCs up-regulated
CXCR3 expression in CD4 T cells, whereas CCR3
expression remained at baseline levels, indicating
Rv0577 participated in adaptive immunity by directing
T cell immune responses to a Thl polarization.
Protection against TB depends on the rapid genera-
tion of effector memory T cells capable of producing
IFN-. These cells are believed to be central compo-
nents of acquired immunity and are the basis for
successful vaccination against TB (43). Furthermore,
antigen-bearing DCs regulate the diverse pattern of
effector memory CD4/CD8 T cell development in
different tissues (45). After M. tuberculosis infection,
CD4 and CD8 T cells expand into effector cells and
then differentiate into long-lived memory cells (46).
Evidence that these cells potently and specifically in-
hibit the growth of the intracellular bacteria M. tuber-
culosis has been shown in vitro, whereby they displayed
macrophage antimycobacterial activity, and in vivo,
when they promote the survival of infected mice (47).
Furthermore, these cells expand in the spleens of mice
infected with M. tuberculosis (47). The findings have
significant implications for the design of vaccines and
immunization strategies for the protection against M.
tuberculosis infection.
In general, effector memory T cells are known to
express the CD44highCD62Llow surface phenotype.
CD44 is a surface protein required for lymphocyte
extravasation to inflammatory sites and its up-regula-
tion is a marker for all memory T cells (48). CD62L is
a lymph node homing receptor that is down-regulated
on activation of T-cell populations (49). In murine
models of M. tuberculosis and M. bovis infection, accu-
mulation of CD4 T cells with decreased CD62L and
increased CD44 expression at the site of infection has
been reported (50). Also, IFN- producing cells have
been described as bearing a CD44high and CD62Llow
phenotype (50).
In our work, we demonstrated that a population of
CD44highCD62Llow CD4/CD8 effectors was specifi-
cally generated from splenic T cells of M. tuberculosis-
infected mice in response to DC-bearing Rv0577, indi-
cating that Rv0577 acts as a specific recall antigen. In
this regard, Rv0577 could be a potent adjuvant trigger-
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ing Th1-mediated immune responses. In addition,
TLR2 has a particularly important role in the mainte-
nance of memory Th1 responses in M. tuberculosis
infection. In addition, the use of TLR2 agonists as T-cell
antigens in TB vaccines may be important, since these
molecules may directly enhance CD4/CD8 T-cell
memory responses and thus confer protective immu-
nity against M. tuberculosis (51). Since our study focused
on murine DCs in vitro, and the TB model for humans
is different from the murine model in the aspect of the
pathogenesis and immunological events, further work
will be needed to extend these findings to human DCs
from individuals infected with M. tuberculosis.
Nevertheless, these findings conclusively demonstrate
that the Rv0577 plays a critical role in the activation of
DCs in a TLR2-dependent manner and the initiation of
the adaptive immune response by polarizing the develop-
ment of T cells to a Th1 response. These novel findings
about the role of the Rv0577 will be useful in the design of
new strategies to prevent many chronic diseases caused by
M. tuberculosis.
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